3-氨基-4-甲氧基-4-氧代丁酸盐酸盐 | 91588-23-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基-4-甲氧基-4-氧代丁酸盐酸盐
• 英文名称: aspartic acid methyl ester hydrochloride
• 英文别名: H-DL-Asp(OMe)-OH HCl；3-amino-4-methoxy-4-oxobutanoic acid;hydrochloride
• CAS: 91588-23-7
• 化学式: C₅H₉NO₄*ClH
• 分子量: 183.592
• InChiKey: SCGWHMHVOQPGLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.62
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  89.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-氨基-4-甲氧基-4-氧代丁酸盐酸盐 在 sodium tetrahydroborate 、 sodium azide 、 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 DL-4-azido-3-tert-butoxycarbonylamino-butyric acid methyl ester
  参考文献：
  名称：

  Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

  摘要：

  An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.04.069
• 作为产物：
  描述：

  甲醇 、 DL-天门冬氨酸 在 盐酸 作用下， 以100%的产率得到3-氨基-4-甲氧基-4-氧代丁酸盐酸盐
  参考文献：
  名称：

  Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

  摘要：

  An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.04.069

文献信息

• A convenient method for the enantiomeric separation of α-amino acid esters as benzophenone imine Schiff base derivatives
  作者：Hu Huang、Wen Jun Xu、Jing-Yu Jin、Joon Hee Hong、Hyun-Jae Shin、Wonjae Lee

  DOI：10.1007/s12272-012-0609-6

  日期：2012.6

  the separation of α-amino acid esters as benzophenone Schiff base derivatives on coated chiral stationary phases (CSPs) (Chiralcel OD-H, Chiralcel OD, Chiralpak AD-H, Chiralpak AD, and Chiralpak AS) or covalently immobilized CSPs (Chiralpak IA, Chiralpak IB, and Chiralpak IC) derived from polysaccharide derivatives is described. Benzophenone imine derivatives of α-amino acid esters were readily prepared

  一种方便的液相色谱方法，用于在涂层手性固定相 (CSP)（Chiralcel OD-H、Chiralcel OD、Chiralpak AD-H、Chiralpak AD 和 Chiralpak AS）上或共价分离作为二苯甲酮席夫碱衍生物的 α-氨基酸酯描述了源自多糖衍生物的固定化 CSP（Chiralpak IA、Chiralpak IB 和 Chiralpak IC）。通过在 2-丙醇中搅拌二苯甲酮亚胺和 α-氨基酸酯的盐酸盐，很容易制备 α-氨基酸酯的二苯甲酮亚胺衍生物。色谱分离以1.0 mL/min的流速和254 nm的检测波长进行；0.5% 2-丙醇/己烷 (v/v) 用于 CSP。总的来说，Chiralpak IC 的分辨率优于其他 CSP。此外，
• [EN] HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE<br/>[FR] DÉRIVÉS D'HYDROXY FORMAMIDE ET LEUR UTILISATION
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015104684A1

  公开（公告）日：2015-07-16

  Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

  揭示了具有以下化学式（I）的化合物：其中R1、R2和R3如本文所定义，并且制备和使用这些化合物的方法，包括用作BMP1、TLL1和/或TLL2的抑制剂以及用于治疗与BMP1、TLL1和/或TLL2活性相关的疾病。
• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DU PROLIFERATEUR DES PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2003072100A1

  公开（公告）日：2003-09-04

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: (Formula I); wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, aryl (C0-C4) alkyl, aryloxy (C0-C4) alkyl, arylthio (C0-C4) alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C1-C5 alkyl, C1-C5 alkenyl, and arylC0-C3alkyl; (c) T1 is selected from the group consisting of C and N; (d) W is selected from the group consisting of CH2, C(O)N(R21), N(R21), N(R21)CH2, O, OCH2, S, and SO2; and(e) X is selected from the group consisting of C, CH2C, and CCH2.

  本发明涉及以下结构式所表示的化合物及其药学上可接受的盐，公式I：（公式I）;其中：（a）R5选自（C1-C6）烷基，（C1-C6）烯基，芳基（C0-C4）烷基，芳氧基（C0-C4）烷基，芳硫基（C0-C4）烷基，进一步地，当R5是烷基时，R5可以选择与W结合形成一个6元环杂环烷基环，该环与R5基固定的噁唑或噻唑环融合；（b）R9选自C1-C5烷基，C1-C5烯基和芳基C0-C3烷基；（c）T1选自C和N的群；（d）W选自CH2，C（O）N（R21），N（R21），N（R21）CH2，O，OCH2，S和SO2的群；（e）X选自C，CH2C和CCH2的群。
• Peroxisome proliferator activated receptor modulators
  申请人：Conner Eugene Scott

  公开号：US20050107449A1

  公开（公告）日：2005-05-19

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, aryl (C 0 -C 4 ) alkyl, aryloxy (C 0 -C 4 ) alkyl, arylthio (C 0 -C 4 ) alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C 1 -C 5 alkyl, C 1 -C 5 alkenyl, and arylC 0 -C 3 alkyl. (c) T 1 is selected from the group consisting of C and N, (d) W is selected from the group consisting of CH 2 , C(O)N(R21), N(R21), N(R21)CH 2 , O, OCH 2 , S, and SO 2 ; and (e) X is selected from the group consisting of C, CH 2 C, and CCH 2

  本发明涉及由以下结构式表示的化合物及其药学上可接受的盐，式I（式I）; 其中：（a）R5选自由（C1-C6）烷基，（C1-C6）烯基，芳基（C0-C4）烷基，芳氧基（C0-C4）烷基，芳硫基（C0-C4）烷基组成的群体，此外，当R5为烷基时，R5可以选择性地与W结合，形成与R5基固定的噁唑或噻唑环融合的6元环杂环烷基环; （b）R9选自由C1-C5烷基，C1-C5烯基和芳基C0-C3烷基组成的群体；（c）T1选自由C和N组成的群体；（d）W选自由CH2，C（O）N（R21），N（R21），N（R21）CH2，O，OCH2，S和SO2组成的群体；（e）X选自由C，CH2C和CCH2组成的群体。
• DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1001971A1

  公开（公告）日：2000-05-24